FDA approves blood cancer therapeutic from AbbVie and Genmab
AbbVie and Genmab recently received approval from the US FDA for their joint venture, the blood cancer therapy epcoritamab, sold under the brand name EPKINLY.
Epcoritamab is the first therapy of the sort to be approved by the FDA for relapsed or refractory large B-cell lymphoma, under their accelerated approval programme. The treatment is the only T-cell engaging bispecific antibody currently on the market.
The therapy is used to treat an advanced form of large B-cell lymphoma, a cancer that starts in the lymphatic system affecting B cells, with new cases occuring in 150,000 people worldwide. The patients receiving this therapy must have received at least two previous forms of treatment to be eligible.
"DLBCL is an aggressive cancer type that can rapidly progress and resist treatment. The FDA approval of EPKINLY represents a new treatment mechanism of action for third line DLBCL patients. As a non-chemotherapy, single-agent treatment for DLBCL patients, we hope that EPKINLY can effectively treat this aggressive cancer type and can be used for patient care quickly and in an off the shelf form for physicians," stated Thomas Hudson, Senior Vice President of R&D and Chief Scientific Officer at AbbVie.
"The approval is just the first step, with our partner Genmab, towards a shared goal of developing a core therapy for patients with B-cell malignancies."
Epcoritamab showed a positive and durable response upon testing, leading to the approval. Approvement further than the accelerated approval will hinge on the results from confirmatory clinical trials. The treatment is currently undergoing Phase III randomised controlled trials to test its use as a mono- or combination therapy in a range of blood cancers.
AbbVie is working on an expanded oncology portfolio with Genmab, leading to this focus on blood cancers with a view to advance the treatment pipeline. Epcoritamab is the third approval for a blood cancer treatment from AbbVie.
"Patients with DLBCL who relapse or are refractory to currently available therapies have limited options. Generally, the prognosis for these patients is poor and management of this aggressive disease can be challenging," explained Tycel Phillips, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope Medical Centre.
"Epcoritamab is a subcutaneous bispecific antibody that offers an additional treatment option for this patient population. With this approval, patients who are in need of additional therapy may have the opportunity to receive epcoritamab after failure to respond or relapse after two or more systemic therapies."
Source: AbbVie News Center. EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [Date accessed 22/05/2023].
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance